The Antibiotic Paradox
Why Nobody Can Justify Building the Medicine We’ll Need Most In April 2019, a small California biotech called Achaogen filed for bankruptcy. Ten months earlier, the company had done something genuinely rare: it won FDA approval for a new antibiotic,…